MedTrace Logo

Efficacy and Safety of Etoricoxib in Acute Ankle Sprain: A Double-Blind Comparative Study Among 2 Treatments Protocols

NCT00525993 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2008-10-21

No results posted yet for this study

Summary

The investigators will study 2 doses of etoricoxib to prove that 60 mg once daily will be non-inferior to etoricoxib 90mg daily (for 14 days) in the treatment of acute ankle sprain in sports. The investigators objective is to discuss the point that the investigators will follow the minimal dose that is effective for the treatment of this acute condition in orthopedic.

Conditions

  • Sprains and Strains
  • Contusions

Interventions

DRUG

etoricoxib 90mg 14 days

each patient in this group will receive 90mg once daily, for the 14 days treatment.

DRUG

etoricoxib 60mg daily for 14 days

Patients in this group will receive 60mg of the drug, daily

Sponsors & Collaborators

Principal Investigators

  • Rogerio T Silva, MD, PhD · NEO - Orthopedic Sports Medicine Research Center

  • Lidia F Souza, PT · NEO - Orthopedic Sports Medicine Research Center

  • Cristiano FS Laurino, MD · NEO - Orthopedic Sports Medicine Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-08-31
Completion
2009-09-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00525993 on ClinicalTrials.gov